ACB - Aurora Cannabis Inc.

NYSE - NYSE Delayed Price. Currency in USD
5.64
-0.15 (-2.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.79
Open5.73
Bid5.64 x 21500
Ask5.72 x 27000
Day's Range5.64 - 5.87
52 Week Range4.58 - 12.52
Volume9,176,107
Avg. Volume11,766,517
Market Cap5.737B
Beta (3Y Monthly)2.47
PE Ratio (TTM)26.11
EPS (TTM)0.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 5 Top Stock Trades for Monday: ROKU, ACB, VMW, CRM, BA
    InvestorPlace

    5 Top Stock Trades for Monday: ROKU, ACB, VMW, CRM, BA

    Wall Street is still nervous and for good reason. The economic global wars are escalating especially between the US and China. Just Friday and ahead of the G7 meetings, China announced resuming its tariffs on US autos. So the politicians continue to pick on headline scabs and cause upside breakout setups to fail at inopportune moments. Simply put, homework is hostage to headlines during this period.Nevertheless, here are the top stocks trades for today: Roku (NASDAQ:ROKU), Aurora Cannabis (NYSE:ACB), VMware (NYSE:VMW), Boeing (NYSE:BA), and Salesforce.com (NYSE:CRM). Top Stock Trades for Monday No. 1: ROKUInvestorPlace - Stock Market News, Stock Advice & Trading TipsThere is too much love for the ROKU stock. So I shorted it almost exactly at the top. My thesis was simple but I think it's time to change my mind on that.Short term, there could be more downside perhaps to close to the open gap at $110. But eventually my take on it is to stop selling the rips and buying the dips in ROKU stock. So I would chase it back to new highs if it closes above $143 per share.Meanwhile, ROKU stock fell on Friday but there should be support down to 133 and $127 per share. Below that it could trigger the gap fill move. So I wait patiently for the level breaks and chase them in that direction. * 7 Retail Stocks to Buy on the Dip Fundamentally, I've been a critic of Roku because they've been in business for 16 years and they still haven't figured out how to be sustainability profitable. But maybe that was because the environment wasn't conducive for their business model.Now that Netflix (NASDAQ:NFLX) established fact that the world wants to cut the cord and stream content, Roku has a better setup because it aggregates content so there will be strong demand for its services. based on this, it's better to trade the ROKU stock than try to judge it on its lack of success in the past. The future prospects are not going to be like what has happened most of those 16 years. Top Stock Trades for Monday No. 2: Aurora Cannabis (ACB)Cannabis stocks are falling off a cliff after incredible hulk blah last year. But one stock stood out among all the high-profile names of late. ACB stock has held up better than most. This is not to say it's doing well except in relation to the rest. Even Canopy Growth (NYSE:CGC) which was once considered the cream of the crop cannot find the bottom. They are all in a technical breakdown patterns setting lower lows for weeks.Meanwhile ACB stock has been managed to hold just above a bearish pattern trigger. It even manage to set a few higher-lows recently. But since its chart is still in a negative channel, then I expect at some point that trend line will break up words.But the immediate goal for bulls is to hold ACB from triggering a bearish pattern that would target $4.70 per share. They can do that by holding above $5.50 now. Else there might be more pain ahead.Eventually and if pot stocks have any future, I expect that the sectors rebounds and ACB stock should lead the charge. It's closest to that since it's showing relative strength now. So this stock is on the watch list and the upside triggers could start as early as $6.20 per share. If that happens it would invite more momentum buyers and cause shorts to cover and book their profits.Since the bulls of ACB stock have so far been able to maintain the line in such negative sector-wide action, the upside scenario looks a little more likely than the breakdown. If I am long ACB stock and have not bailed on it, now is not the time to do it for the same reasons stated here. Top Stock Trades for Monday No. 3: VMware (VMW)VMW stock has had a terrible year so far. It's lagging behind since it's only up half as much the S&P 500. Moreover, VMW is down 30% from the March highs. But the opportunity to buy VMW stock is fast approaching. On Friday the stock fell 8% on a decent earnings headline.It has fallen so far that it is reaching a long term pivot zone. These are usually support because bulls and bears have a history of tough fights there. This creates congestion and should give the VMW stock bulls the chance to stabilize the stock and mount their bounce rally.Specifically, VMW stock is just above the last two bottoms around the Christmas corrections. So unless there is something new developing these should hold. VMW $130 per share was pivotal in early 2018 and it should again play an important part soon.Since they don't ring bells at bottoms, I can start a long position with an appropriate stop. It's best to see VMW stock rise above $145 to trigger some buying to accelerate. Conservatively, I can wait it out until a clear trough develops but the downside risk from the charts seems reasonably low. Top Stock Trades for Monday No. 4: Boeing (BA)BA stock was almost impossible to short. Every dip was a buying opportunity. But the sad events of the Boeing 737 Max crashes changed that fact. Now the headlines are more negatively impactful than positively.The headlines are fast and furious and the BA stock bulls are in pain.I would buy BA stock here but this is for the long term. This is after all still a duopoly where both suppliers are overbooked for a decade in advance. So these operational and political problems here are transitory. So this is a classic scenario of this too shall pass.BA stock sells at a 41 price to earnings ratio and pays a respectable dividend. So owning it at these levels is not paying for a lot of bloat. Most of the perceived froth has already been sold out of it.BA stock was up on Friday even though the stock markets were down almost 2%. So this is encouraging but there is a band of resistance through 380 per share. But if the BA bulls can push through it then they target a $50 rally from there. Top Stock Trades for Monday No. 5: CRMThis is the company that invented the cloud. It started years ago when no others were pursuing using the internet for business operations. They battled the behemoth Microsoft (NASDAQ:MSFT) and won. This should have been a sign that CRM stock had much higher levels to go.Indeed, it's is up 162% in five years. On Friday, CRM stock spiked another 5% on a reaction to an excellent earnings report (and then fell with the broader market). They beat all expectations and raised their forward guidance. This silenced a lot of criticism of their acquisitions efforts. Clearly this is a team that is executing on plans perfectly and the only way for the Salesforce.com stock is up. * Stock Market Today: Trump's Tweets Rattle Investors, Foot Locker Trips So If I am long the stock for the long term then I am lucky and stay in it. I personally had longs as a binary bet on the earnings and it paid quickly. But I would buy CRM stock when it closes above $161 per share. From their the upside potential is for another $15 rally in the next few months. There is some short term concern from the open earnings gap.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room for free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy on the Dip * 7 Marijuana Stocks With Critical Levels to Watch * 7 Internet of Things Stocks to Buy Now The post 5 Top Stock Trades for Monday: ROKU, ACB, VMW, CRM, BA appeared first on InvestorPlace.

  • Financial Services for US Cannabis Firms Gaining Traction
    Market Realist

    Financial Services for US Cannabis Firms Gaining Traction

    New York’s Carolyn Maloney expressed optimism about the House approving the SAFE Banking Act. The bill would open banking access to the cannabis industry.

  • Hexo Stock Continues to Feel the Effects of Cannabis Industry Issues
    InvestorPlace

    Hexo Stock Continues to Feel the Effects of Cannabis Industry Issues

    Hexo Corp (NYSE:HEXO) continues to feel the impact of its underwhelming Q3 earnings, a slower than expected recreational cannabis market in Canada, and concern over corporate leadership in the industry. Hexo stock is down 13% from Monday's open, and is now trading right around the $4 mark.Source: Shutterstock This continues a slide that began after HEXO hit an all-time high of $8.28 in April, and worsened after another quarter of red ink and the departure of its co-founder from his executive role. HEXO Underwhelmed in Q3On June 12, HEXO reported Q3 earnings and failed to impress investors. The company missed badly on revenue ($13 million CAD compared to the $14 million analysts were looking for) and the red ink was worse than expected, with a quarterly loss of $7.75 million -- up from a loss of $1.97 million the previous year. The company announced plans to enter the U.S. CDB market through a joint venture with Molson Coors Brewing Co (NYSE:TAP), but that is fast becoming a crowded field and investors weren't overly impressed. Hexo stock dropped over 8% on the results.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Marijuana Stocks That Could See 100% Gains, If Not More HEXO is expected to report Q4 earnings in September. Investor Nervousness Around Cannabis IndustryMany investors piled onto Canadian cannabis stocks over the past year, looking for the legalization of recreational pot in Canada to result in a boom market. The reality has been a little harsh for some.Slower than expected initial sales of recreational pot led to cannabis stocks tumbling in the days after recreational marijuana use was legalized in Canada last October. There were no line-ups at Canadian cannabis retailers and product shortages were reported as a result of glitches in distribution and production. While the situation has improved, recreational pot still isn't exactly flying off the shelves in Canada.Adding to investor unease, 2019 has seen considerable drama among Canadian cannabis companies, and HEXO has not been immune. In January, the CEO of Aphira (NYSE:APHA) left the company amid allegations of improprieties regarding acquisitions in Latin America. On July 10 the CEO and co-founder of Canopy Growth (NYSE:CGC) was forced out of his role, and didn't leave without igniting controversy over his dismissal.Just days later on July 18, HEXO's co-founder stepped down from his role of Chief Brand Officer, although he retained his seat on the board.The most recent headlines were centered around CannTrust Holdings (NYSE:CTST), which became the center of Health Canada and Ontario Securities Commission investigations over illegal cannabis cultivation at one of its facilities. The fallout there has included the firing of the CannTrust Holdings CEO and the forced resignation of the company's co-founder and chairman. The series of leadership shakeups and missteps has certainly not helped cannabis stocks in 2019, although the corporate transitions are expected to put many of these companies in stronger positions for the long term. How Does Hexo Stock Performance Compare to Cannabis Cohorts?Even after this week's 13% drop and a decline in Hexo stock price of around 40% since it reported Q3 earnings in June, HEXO is performing reasonably well on the year compared to its fellow Canadian cannabis stocks. Year-to-date growth is 6.5% for HEXO, while Aurora Cannabis (NYSE:ACB) is up 11% and Aphira has gained over 8%.However the biggest of the Canadian cannabis producers Canopy Growth has lost 13% since the start of the year. CannTrust Holdings -- the company that kicked off the latest round of concern about the industry -- has dropped some 64% so far in 2019. * 7 Retail Stocks to Buy on the Dip The question for HEXO investors is whether the company's Q4 earnings are going to going to be as underwhelming as Q3's were. If so, the Hexo stock price slump that started in April could well continue through the fall. And HEXO doesn't have far to drop before it goes into the red for 2019…As of this writing, Brad Moon did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy on the Dip * 7 Marijuana Stocks With Critical Levels to Watch * 7 Internet of Things Stocks to Buy Now The post Hexo Stock Continues to Feel the Effects of Cannabis Industry Issues appeared first on InvestorPlace.

  • Market Exclusive

    Why Did Aurora Cannabis Acquire Hempco Food and Fibre?

    Following the completion of a plan of arrangement, Aurora Cannabis (NYSE: ACB) (TSX: ACB) has acquired all of the issued and outstanding common shares of Hempco Food and Fiber (TSX-V: HEMP). To acquire shares of Hempco not already owned by Aurora, the company invested approximately C$63.4 million on a fully diluted basis. Hempco is now a wholly-owned subsidiary of Aurora. The […]The post Why Did Aurora Cannabis Acquire Hempco Food and Fibre? appeared first on Market Exclusive.

  • Canopy Growth Stock Is Short on Fundamentals, But High on Potential
    InvestorPlace

    Canopy Growth Stock Is Short on Fundamentals, But High on Potential

    You don't have to look far to see evidence that publicly traded marijuana companies are incredibly volatile. And that assessment is the same for the top players like Canopy Growth (NYSE:CGC). Just in this month alone, Canopy Growth stock has dropped nearly 23%. And since the end of April, shares have shed slightly more than half its market value.Source: Shutterstock Without any hesitation, it's a sickening decline. Just to make matters worse, stakeholders no longer have the buffer that CGC stock was up on a year-to-date basis. At least at the time of writing, that's no longer true. Since January's opening price, the weed company is now looking at a more than 5% loss.As Noel Gallagher formerly of Oasis fame might ask, where did it all go wrong for CGC stock? According to The Motley Fool's Sean Williams, one of the reasons is the company's goodwill.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn a non-financial context, goodwill actually sounds like a good thing. Certainly, we can use more of it, from in our daily interactions all the way up to in the highest political offices. But from an investor's point of view, goodwill doesn't always live up to its linguistic implications.According to an Associated Press report on the subject, goodwill is the premium that companies place on a bought-out organization's actual assets, such as property, plants and equipment. In other words, goodwill represents vague concepts, such as reputation or corporate culture.This premium is fine during a bull market. But to Williams' point, under iffy circumstances, excessive goodwill may lead to a write-down of its assets. And for a pot investment like Canopy Growth stock, a write-down is the last thing it needs. Why Goodwill Isn't So Bad for CGC StockWilliams makes a compelling argument why you should avoid Canopy Growth stock. Although I'm still bullish on weed, I understand where he's coming from. And especially if you're a conservative investor, I would second his assessment. * 10 Marijuana Stocks That Could See 100% Gains, If Not More Moreover, the Associated Press prepared a great argument for why investors should fear blue-chip S&P 500 companies with excessive premiums for intangibles. Back in the summer of 2016, the news agency wrote that goodwill represented $2.5 trillion of the index's balance sheet. For context, that's roughly 12% of U.S. gross domestic product.Thus, we arrive at a logical argument. If excessive goodwill is bad for storied power players, it must be downright terrible for CGC stock. If we're strictly looking at the financials, then of course, you shouldn't expose yourself to Canopy Growth stock.But let's also remind ourselves that legal marijuana isn't exactly logical. More often than not, companies like CGC are narrative-driven affairs fueled by emotions.That's a far different take from S&P 500 organizations. Specifically, the reason why excessive premiums on intangibles are undesirable for blue chips is that their markets are limited. For example, a tech firm can only sell so many computer chips. If such companies take a hit on goodwill, then it may severely impact pre-tax earnings. Unsure of how they will recoup the losses, observing investors may head for the exits.But with Canopy Growth stock, we don't know what the potential limits are. For right now, the actual limits are whatever the Canadian market can support, which admittedly is not much.But what if we have the long-shot event where the U.S. legalizes marijuana at the federal level? I'd say for CGC that at that point, goodwill isn't a liability, it's a bonus. Canopy Growth Stock Is All About the ReachAt the end of the day, here's why Canopy Growth stock and its ilk like Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) have stunk up the markets. They're all reaching for the potential that international markets may provide.For example, Canopy has secured the right to buy Acreage Holdings (OTCMKTS:ACRGF) on a contingency. And that contingency is that the U.S. fully legalizes weed.Will it happen? I think it will, but I don't have a crystal ball. Clearly, most Canadian cannabis companies think so as well, which is why they're positioning themselves for that possibility. When they do this, their acquisitiveness naturally lifts goodwill.If political events don't go according to plan, probably all weed stocks will collapse. But if legalization does pan out -- and there's compelling evidence that it will -- CGC goes to the moon. That's the charm and the pitfall of marijuana.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Canopy Growth Stock Is Short on Fundamentals, But High on Potential appeared first on InvestorPlace.

  • 3 Pot Stocks With a Huge International Presence
    Motley Fool

    3 Pot Stocks With a Huge International Presence

    These marijuana stocks have cultivation, export, or research deals with at least one dozen countries outside of Canada.

  • Aphria Makes ParcelPal Deal, Son Wins License
    Market Realist

    Aphria Makes ParcelPal Deal, Son Wins License

    Today, Aphria announced a deal with ParcelPal to deliver medical cannabis to patients. Also, Cole Cacciavillani's son has won a cannabis store license.

  • Smokable Hemp: Banned in North Carolina in May 2020
    Market Realist

    Smokable Hemp: Banned in North Carolina in May 2020

    On May 1, smokable hemp will be banned in North Carolina. The state passed the North Carolina Farm Act, removing smokable hemp from its permissible list.

  • When Exactly Will Aurora Cannabis Stock’s Downtrend End?
    InvestorPlace

    When Exactly Will Aurora Cannabis Stock’s Downtrend End?

    Aurora Cannabis (NYSE:ACB) is stuck in a downward trajectory in the stock markets.Source: ElRoi / Shutterstock.com Weak quarterly earnings from Tilray (NASDAQ:TLRY) and a regulatory violation from CannTrust Holdings (NYSE:CTST) are scaring investors away from the cannabis sector. When Aurora reports its quarterly results on Sept. 15, what should investors expect? Strong Preliminary SalesAurora stock already reflects the upside quarterly results. On Aug. 6, Aurora posted preliminary fiscal fourth-quarter revenue in the range of $100 million CAD to $107 million CAD. This is up sharply higher from last year's $19.1 million in revenue. Fiscal Q4 2019 net cannabis revenue will be in the range of $90 million to $95 million. Every business segment is firing on all cylinders, with activity strong both internationally and in Canada. Medical and consumer markets will be up year-over-year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe fiscal 2019 revenue of between $249 million and $256 million still values Aurora stock at a price-to-sales in the 30 times range. Even though ACB stock fell from the $10 high in March to the $5.80 range recently, the markets expect strong revenue growth. Aurora cannot report any slowdown in sales nor may it miss on output. For Q4, the production available for sale will be in the upper end of the range between 25,000 kilograms and 30,000 kilograms. * 10 Marijuana Stocks to Ride High on the Farm Bill Despite a forecast for exceeding key performance indicators, markets are no longer bidding the stock higher. In the long term, gross margins will rise as will kilograms of cannabis sold. And as cash costs per gram produced falls, the company will earn a profit. For now, Aurora's adjusted EBITDA is not yet positive. Poor results from Tilray are creating an air of caution for Aurora ahead of its earnings report.CannTrust's disclosure of growing in unlicensed rooms shook away the inherent trust investors had for the company and for the sector as a whole. Health Canada is leaving CannTrust in the dark on what happens next. This is frightening. Regulations imposed on other cannabis firms might slow their growth rates. Canopy's Q1 Miss Hurts ACB StockOn Aug. 15, Canopy Growth (NYSE:CGC) reported an EBITDA loss of $92 million CAD in the first quarter. Even though harvest rose 183% quarter-over-quarter and over three-fold year-over-year, losses mounted. But Canopy wrote down a $1.18 billion CAD warrant liability. It has no other big costs ahead and expects to accelerate the rate of output from here.To shore up its balance sheet, Aurora upsized its credit facility by $160 million CAD to $360 million CAD. The company is bolstering its cash reserves to make an acquisition. Its chief financial officer Glen Ibbott said:The upsizing of our credit facility and broadening of the lending syndicate to include additional Schedule 1 Canadian Banks is further recognition that our best-in-class production facilities lead the industry. Access to this non-dilutive capital is a core funding source the company intends to utilize as it further executes on its strategic growth initiatives.As the valuation of other potential takeover targets falls, Aurora is positioned to buy them at a better price. Unfortunately, investors no longer have the patience to reward firms accumulating debt.Conservative investors tired of waiting for profits should avoid Aurora stock -- and cannabis stocks in general. Conversely, those betting on Aurora announcing a partnership with a major S&P 500 company would get rewarded if it happens. In the interim, Aurora Cannabis is working towards positive EBITDA.Last week, Aurora completed its acquisition of Hempco Food and Fiber for just over $60 million CAD. It issued over 2.6 million shares to pay for the deal. My Takeaway on ACB StockShorts have the upper hand on Aurora Cannabis stock for the time being. At a short float of 11%, the stock will not bounce back until sentiment improves. The stock may retest yearly lows in the coming weeks. If that happens, long-time investors will need to decide if they should buy more shares or keep holding it.As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post When Exactly Will Aurora Cannabis Stock's Downtrend End? appeared first on InvestorPlace.

  • Will Hexo Stock Be Around for the Long Haul?
    InvestorPlace

    Will Hexo Stock Be Around for the Long Haul?

    When it comes to Canadian cannabis companies, Hexo (NYSE:HEXO) doesn't always get the recognition it deserves. Hexo stock is often seen as the little brother to bigger players like Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:CGC). Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut if you're looking to get in at the ground floor with a growing cannabis company, HEXO isn't a bad option. The company's sales have grown by massive amounts over the last 12 months. And the company predicted its revenue will double over the next quarter. Of course, many investors are hesitant given some of the recent uncertainty in the Canadian cannabis industry. Here are three things you need to know before investing in Hexo stock. The Cannabis Industry Is On Unsteady FootingThere's been a lot of volatility in the cannabis industry recently. First, there was the revelation that CannTrust (NYSE:CTST) was illegally growing marijuana in unlicensed rooms. And most recently, Canopy Growth released an abysmal earnings report showing that the company isn't as profitable as many investors believed. All of this has caused marijuana stocks across the board to fall.The cannabis industry is going to be huge, but it's still unclear which companies will be around to cash in on it. At this point, it's impossible to predict which company will fall victim to regulatory issues or plunging sales next. Hexo Stock Isn't Yet ProfitableHexo's most recent earnings report showed that the company achieved huge growth over the past year. In the third quarter of 2018, the company's sales were a mere CAD $1.24 million. This year, that figure came in at CAD $15.9 million.However, like many cannabis companies, Hexo is not yet profitable. The company may have earned more during the third quarter, but it also spent a lot more money. Its total operating expenses came to CAD $24.1 million during the third quarter.And the company is still held back by its production capacity. However, the company did open a 1-million-square-foot greenhouse in April so it will be interesting to see how that impacts the company during its Q4. HEXO Has Long-Term PotentialLooking forward, Hexo stock does have a lot of long-term potential. The company's sales are impressive and it currently holds a 30% market share in Quebec.And Hexo is actively working to improve its production capacity. In March, the company announced it planned to acquire the Toronto-based Newstrike Brands. Once these facilities are fully operational this will give Hexo an additional 470,000 square feet in production space. The company currently makes most of its revenue from recreational and medicinal marijuana sales. But its recent partnership with Molson Coors (NYSE:TAP) sets the stage for Hexo to lead the market in cannabis-infused beverages, once legalized. * 10 Marijuana Stocks That Could See 100% Gains, If Not More My advice with Hexo is to proceed with caution. The fundamentals look promising but there are just too many unknowns going forward. As of this writing, Jamie Johnson did not hold a position in any of the aforementioned stocks. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Will Hexo Stock Be Around for the Long Haul? appeared first on InvestorPlace.

  • Why Aurora Cannabis May Have Made a Big Mistake By Not Partnering With a Beverage Company
    Motley Fool

    Why Aurora Cannabis May Have Made a Big Mistake By Not Partnering With a Beverage Company

    The battle for the edibles market, and beverages, in particular, is about to heat up, and Aurora Cannabis could be in danger of falling behind its peers.

  • Down 25% in a Month, CGC Stock Could Fall Further
    InvestorPlace

    Down 25% in a Month, CGC Stock Could Fall Further

    Canopy Growth (NYSE:CGC) stock has taken a pounding. Shares are down nearly 25% in the past month, from $35.40 per share to $26.57 per share. The investor exodus from marijuana stocks has been brutal.Source: Shutterstock With excess supply outgunning demand, it's no wonder the bull case for pot stocks is tough to justify. But can investors expect a rebound in Canopy Growth stock? Let's take a closer look at the future of CGC shares. Recent Performance of CGC StockCGC released earnings on Aug. 14. For the quarter ending June 30, net revenue was C$90.5 million, down from C$94.1 million in the prior quarter. Overestimating demand for CBD oils and capsules, Canopy lost out while its peers such as Aurora Cannabis (NYSE:ACB) continued to grow revenue. As a result, CGC saw operating losses of C$123.1 million for the quarter.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDespite oversupply in the market, CGC and the other Canadian cannabis names continue to ramp up production. Canopy harvested about 41,000 kg during the quarter. But sales were only 10,549 kg or kg equivalents. Like Aurora Cannabis, Canopy has gotten ahead of itself in its fast drive to scale operations.But is short-term thinking not the way to go with cannabis stocks? As InvestorPlace contributor Luke Lango wrote on Aug. 19, "there is still visibility for Canopy to one day be a $50 to 100 billion company." Investors buying in now may see tremendous gains over a long time frame. * 10 Marijuana Stocks That Could See 100% Gains, If Not More What about investors with a shorter time horizon? Is upside priced in, or can investors get a discount? Let's take a look at the valuation of Canopy Growth stock. Valuation: Canopy Growth Stock Still FrothyCanopy Growth stock currently trades at a Enterprise Value/Sales (EV/Sales) ratio of 32.2. This is a discount to the current EV/Sales valuation of Aurora Cannabis. ACB trades at an EV/Sales ratio of 48.2 In terms of other peers in the "cannabisphere," Cronos Group (NASDAQ:CRON) continues to trade at a high valuation (EV/Sales of 150.7). Tilray (NASDAQ:TLRY) trades at a discount to CGC, with an EV/Sales ratio of 31.4.With the recent beat-down of Canopy Growth stock, shares are now a bargain compared to Aurora Cannabis. But, as I wrote earlier this month, Aurora Cannabis seems to have a better growth playbook. By focusing on the medical marijuana space, Aurora is the safer cannabis stock play. But an overlooked risk factor in both cannabis stocks is dilution. The use of share issuance and warrants to finance unprofitable operations minimizes upside for investors. CGC Stock Dilution Risks ContinueThe company's partnership with Constellation Brands (NYSE:STZ) was initially seen as a boost for CGC stock. But as the partnership progresses, it is clear the deal is terrible for shareholders. Constellation's $5 billion dollar investment included the issuance of warrants. These warrants came with certain covenants to protect Constellation from dilution. CGC's proposed buyout of Acreage Holdings (OTCMKTS:ACRGF) triggered a renegotiation of warrants. Due to this revision, CGC was forced to reprice the Tranche B warrants, resulting in a C$1.2 billion non-cash charge.As I wrote on July 29, dilution continues to be a problem for Canopy Growth stock. This dilution risks goes beyond the Constellation partnership. $600 million in convertible debt comes due in 2023. The conversion price is set at $48.18 a share. If CGC stock continues to languish under this strike price, the company will likely need to raise more capital once the notes mature.Of course, Canopy Growth could be profitable by 2023, and would have an easier time refinancing the debt. But investors should take the dilution risk seriously. With much of Canopy's potential priced into shares, dilutive capital raises could cap the stock's upside potential. Bottom Line: The Canopy Sell-Off Isn't OverCanopy stock is down more than 50% from its 52-week high. But shares could go lower. With Canadian market growth nonexistent, Canopy needs U.S. legalization fast in order to move the needle. With federal legalization still years off, CGC will likely continue to burn cash as it scales up operations. The partnership with Constellation Brands provides plenty of capital to keep the lights on. But the terms of the partnership give Constellation an easy way to takeover the company at a discount.So what's the call on CGC stock? Investors should continue to wait on the sidelines until the situation improves. If Canopy Growth stock falls another 50% (or more), there could be a buying opportunity. I do not deny that we are the early stages of the marijuana legalization story. But investors need to wait until hype has dissipated to consider stocks such as CGC.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Down 25% in a Month, CGC Stock Could Fall Further appeared first on InvestorPlace.

  • 7 Marijuana Stocks With Critical Levels to Watch
    InvestorPlace

    7 Marijuana Stocks With Critical Levels to Watch

    [Editor's note: This story will be updated each week with new stocks and analysis. Please check back often for Mark's latest take on marijuana stocks.]In financial markets, there are certain levels that are more important than others with regards to the amount of supply and demand that exists at them. In addition, in financial markets, prices are always doing one of three things. They are going up, going down or staying the same.When understood and applied correctly, technical analysis of the marijuana stocks should be an illustration of these dynamics in this sector.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut technical analysis has a bad reputation and I can understand why. Most technical analysts don't seem to understand what they are supposed do. They mindlessly look at markets and try to identify patterns without understanding what they are supposed to mean.Even worse, some analysts are proponents of strange methods like Elliot waves and Gann theory. These methods are like Bigfoot. They are fun to talk about, but they aren't real. * 10 Marijuana Stocks That Could See 100% Gains, If Not More Knowing where the important levels are can help you profit. For example, suppose you want to buy a stock when it gets to $5 a share. If there is support at $6 and you don't realize it, the stock could drop to $6 and then rally. You would have missed a nice profit for one dollar because you didn't know about the support. Marijuana Stocks to Watch: Canopy Growth (CGC)Canopy Growth (NYSE:CGC) has been trending lower since the end of April. Since then, the CGC stock share price has dropped by 50%.Even getting rid of idealistic Co-CEO Bruce Linton didn't convince investors that things would turn around. The bottom line here is that Canopy loses a lot of money and shareholders are starting realize this. The latest earnings report showed them posting a loss of CA$257 million.After that earnings report, the stock dropped from $32 to $28 and it has been trending lower since then.If it trades down to the $25.50 level, it may rebound a bit. That is where it found support in December and it is currently oversold. Cronos Group (CRON)Cronos Group (NASDAQ:CRON) grows and sells marijuana.After failing to break resistance around the $14 level, CRON stock has dropped by about 15%. It may keep going lower, because I don't see any well-defined support levels.This stock shows how resistance levels become support and then support becomes resistance. This is an amazing phenomena that few consider.Clearly the $14 level is important here. Those who sold it at $14 in September and December were happy when it went lower. But then, when it went higher, these sellers believe that they have made a mistake. They tell themselves that if it comes back to $14, they will buy it back. This demand will create support. * 11 Stocks Under $10 to Buy Now Support becomes resistance because when the stock goes lower, those who bought it at the support level are now losing money. They tell themselves that if it trades back up to the level, they will sell it to break even. This supply of stock at the level creates resistance. Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB) is a Canadian-based company that grows and sells medical cannabis.Since failing at resistance at the $7 level, ACB stock has trended lower. There is resistance around this level because it was support in June. It the stock rallies back to $7, that level will probably be resistance again.If it continues to trend lower, it may find support around the $5 level. This is because this level was support in November and December.I believe that this company will continue to have difficulties. A large part of the valuation is Goodwill and intangibles assets. This is an issue because these values are extremely hard to calculate, and companies tend to overestimate them. In my opinion that is the case here. CannTrust Holdings (CTST)CannTrust Holdings (NYSE:CTST) is involved in the production and distribution of medical cannabis.Over the past month, there has been support around the $2 level. However, this level seems to be breaking, and this company is facing the very real prospect of bankruptcy. It is currently undertaking a strategic review.This company is now known on Wall Street as Can't Trust Holdings. CTST was recently found to be growing cannabis in unlicensed grow rooms that were literally hidden behind fake walls.Even worse, not only was the senior management aware of this, they seemed to be encouraging it. We know this because they were stupid enough to put it in emails that the Canadian Authorities have seized. * The 10 Best Marijuana Stocks to Buy Now Since then, the company has had to accept product returns and will soon be facing a series of lawsuits by investors who were defrauded. My guess is that other companies are also engaged in this type of illicit activity, and if so we will soon be hearing about them as well. Aphria (APHA)Aphria (NYSE:APHA) produces and sell medical cannabis.Investors should watch for resistance around the $6.30 level. That is because is was a support level from May through July. Remember, those who bought it at $6.30 are losing money, so they decide to sell it if it gets back to the level.However, this level may not be too significant, because it was recently broken to the downside before ACB stock went rallying back up through it. Once a level is broken, it can lose its some of its importance.If it does rally, there will probably be resistance again around the $7.50 level. This level was support in May and June, and then again earlier this month when the stock rallied on what was considered a good earnings release. Supreme Cannabis (SPRWF)Supreme Cannabis (OTCMKTS:SPRWF) produces and sells medical cannabis.SPRWF stock recently found support around the 90-cent level. This level was also support at the end of December.I like this company because its cannabis is sun grown, as opposed to being grown with artificial lights. This method is cheaper and results in a higher-quality product.The company has rallied by over 30% since updating its guidance. The numbers were very impressive. Full year 2020 revenue should be $150 million-180 million CAD. Prior estimates were around $130 million CAD. * 15 Growth Stocks to Buy for the Long Haul For the fourth quarter, the company sees revenue of $19 million CAD versus $3.5 million CAD a year ago. The Street was looking for around $13 million CAD. CURE Pharmaceutical(CURR)CURE Pharmaceutical (OTCMKTS:CURR) develops and manufactures drug formulation and drug delivery technologies.You don't need to be a Market Guru or Master Trader to see that the $4.50 level is important for CURR stock. It was resistance a year ago in August and September, and then again in March.After breaking to the upside in July, it became a support level. Now that the stock has traded lower, it has become a resistance level again.Knowing that there is resistance at this level could help you with your trading decisions. For example, suppose you want to sell it at $5. You need to be aware that it may not get there.Watch how the stock trades around the $4.50 level over the next few days. If it looks like its breaking to the upside, then it could get to your level and it makes sense to be patient. Conversely, if it looks like it is going to fail at this level you may want to sell it because there is a good chance it could go much lower.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post 7 Marijuana Stocks With Critical Levels to Watch appeared first on InvestorPlace.

  • Seize the CBD Opportunity With a Position in Aurora Cannabis Stock
    InvestorPlace

    Seize the CBD Opportunity With a Position in Aurora Cannabis Stock

    CBD, the hemp-derived, non-psychoactive component of cannabis, seems to be everywhere nowadays. The fact is, however, that it's a market in its infancy. Right now, savvy investors are placing their bets on Aurora Cannabis (NYSE:ACB) stock as a vote in favor of the emergent CBD revolution.Source: Shutterstock Granted, not everyone is leaning bullish on Aurora Cannabis stock, and I'll address the critics' arguments even if it marks me as a contrarian and a nonconformist but then, I've been known to go against the grain time and again, so why should today be any different? Get Your Share of CBD Wealth with ACB StockIf you're not convinced of the CBD market's explosive potential, I've got some numbers that ought to change your mind.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAccording to research firm BDS Analytics, the American market for cannabidiol (CBD) will balloon to $20 billion by the year 2024, signifying an astounding compounding annual growth rate of 49%. Meanwhile, a study conducted by Fior Markets projects that the global CBD industry will expand at a compound annual growth rate of 36.3% from 2019 through 2026. * The 10 Best Marijuana Stocks to Buy Now Some people have reported that CBD is effective in alleviating pain, improving sleep disorders, and helping to reduce anxiety, among other benefits.Have I made you a believer in CBD yet?Whether you're seeking solutions to common medical issues or if you just want to profit from this burgeoning cannabis subsector, CBD stocks are a great buy-and-hold in 2019 and ACB stock is a strong contender in this regard. The company proved its commitment to CBD in 2018 when Aurora acquired Agropro, the most prolific producer of hemp at that time in Europe. The company also bought Borela, the sister company of Agropro and a then-established producer and distributor of organic hemp-derived products. Building a CBD Empire, One Acquisition at a TimeBut that wasn't all: also in 2018, Aurora Cannabis acquired the then-undisputed leader in South American hemp cultivation, ICC Labs. This acquisition gave Aurora control over 70% of Uruguay's CBD market in one fell swoop, along with a massive extraction facility that's able to process 150,000 kilograms' worth of CBD product per year.Thus, while other cannabis companies were still exploring their options in CBD, Aurora was proving itself as a dedicated and aggressive early mover in the space.On top of all that, Aurora Cannabis just announced that it has completed its acquisition of hemp-based product provider Hempco Food and Fiber. Much like the ICC Labs takeover, the Hempco buyout will enhance Aurora's ability to process huge quantities of raw hemp for CBD products efficiently and at a relatively low cost. Terry Booth, the CEO of Aurora, is eager to reap the rewards of the company's latest acquisition:Through the addition of Hempco, we have assembled a world-class portfolio of high-quality hemp assets that together form the basis of a strong new operating division that will develop CBD-from-hemp around the world. Here Come the CriticsOf course, there will always be haters and doubters whenever a cannabis company like Aurora makes a big, bold move; what I see as progress, they view as taking on risk. Perhaps that would account for Cliff Asness' AQR Capital Management unloading 7,102,892 shares of ACB, valued in excess of $64 million, a vote of "no confidence" if I ever saw one.Or maybe Asness has been listening to Michael Avery, an analyst at Piper Jaffray, who has complained that Aurora Cannabis can't sell CBD products in Europe "until it receives EU-GMP certification, which could take time."I hate to call Avery "Captain Obvious," but that's a known factor and Aurora is a highly profitable company that evidently doesn't mind waiting for regulatory hurdles to be cleared; if time is the only obstacle to massive profits in Europe, then Aurora will wait patiently and so will I. * 10 Marijuana Stocks That Could See 100% Gains, If Not More The Takeaway on Aurora Cannabis StockHow much longer will it be before the CBD market really takes off and pushes the ACB stock price to new highs? No one can pinpoint an exact date, but I'm fine with buying and holding Aurora Cannabis stock shares in anticipation of CBD riches and hemp-powered prosperity in the near future.As of this writing, David Moadel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Seize the CBD Opportunity With a Position in Aurora Cannabis Stock appeared first on InvestorPlace.

  • Aurora Cannabis Doubles Down on U.S. CBD Market
    InvestorPlace

    Aurora Cannabis Doubles Down on U.S. CBD Market

    Aurora Cannabis (NYSE:ACB) is continuing to spread its bets across product lines and markets far and wide. With a market cap now standing at $5.9 billion, the Edmonton, Canada-based marijuana stock is the second-largest cannabis company in the sector just behind Canopy Growth (NYSE:CGC) of $9.25 billion.Source: Shutterstock On Monday, Aurora Cannabis announced that it completed its acquisition of Hempco Food and Fiber, a producer of hemp-based fiber and nutritional supplements such as CBD products. The aggressive move into the small but rapidly expanding CBD market will give Aurora a definite leg up into penetrating the U.S. market, where sales are starting to boom.Despite news of the expansion, ACB stock closed down slightly and is now trading at $5.84, well off its 52-week high of $12.52.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCertainly, investors have cooled off to ACB stock since earlier this year with many believing it is still overvalued in comparison to Tilray (NASDAQ:TLRY) or Hexo (NYSE:HEXO). Yet, taking a long-term prospective, ACB may be a solid value play if it gets closer to its 52-week low of $4.58. * 10 Marijuana Stocks That Could See 100% Gains, If Not More Here are three key reasons why ACB is a good long-term play: Aurora Cannabis Has Rock-Bottom Production CostsAurora Cannabis has certainly been on an acquisition binge since it was first founded in 2006. The acquisition of Hempco was just the latest in a string of ACB stock acquiring more production assets, including the takeover last year of CanniMed Therapeutics for $1.1 billion as well as MedReleaf in a $3.2 billion.In fact, since 2016 Aurora has closed on 18 strategic acquisitions across the entire cannabis production value chain. But now, it commands enormous scale, with operations in five continents, 25 countries and 15 global production facilities. By 2020, ACB stock will have put online a production capacity of 625,000 kgs per year. Eventually, Aurora Cannabis estimates that average production costs given their huge economies of scale will fall to be well below $1 per gram. The long-term winners of the pot stock market will likely be those producers who can implement scale in order to minimize production costs. The U.S. CBD Market Is Already Alive and KickingThe most important reason for ACB's acquisition of Hempco may be the U.S. hemp market. After the U.S. legalized hemp last year, various CBD products from hemp are expected to pop up in drug stores from coast to coast.CBD can be found in a wide range of healthcare products, including skin ointment, infused beverages and CBD oil. The U.S. CBD space is heating up, and many major retailers want to get into that market. This month, the grocery chain Kroger (NYSE:KR) announced it would start selling Charlotte Web's (OTCMKTS:CWBHF) hemp products. In fact, Canopy Growth is investing about $150 million in building a hemp industrial park in New York state where CBD is already legalized acquired AgriNextUSA last March specifically to expand hemp production. ACB Stock Owns the Supply Chain and Creates Brand EquityACB may be the leader among marijuana stocks in terms of focusing on the high end of the cannabis market in order to maximize average selling price. Aurora Cannabis stock invests heavily in research and development to create a marketable brand name and valuable intellectual property. Through global expansion, Aurora is is spending to buy its own distribution channels and establish leadership in key international markets. Size and ownership of distribution channels should allow ACB stock to focus on the highest margin products, notably branded medical marijuana.The weeks ahead may certainly see choppy waters for ACB stock. But given its long-term fundamentals, size, scale and investment in brand equity, Aurora Cannabis stock will be a decent long-term value if it gets any cheaper.As of writing, Theodore Kim does not have any position in the above-mentioned stocks. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Aurora Cannabis Doubles Down on U.S. CBD Market appeared first on InvestorPlace.

  • James Simons: What Interests Him in the Cannabis Space?
    Market Realist

    James Simons: What Interests Him in the Cannabis Space?

    James Simons is the world’s wealthiest hedge fund manager. He made significant investments in the cannabis sector this year.

  • Motley Fool

    When Will the Big Canadian Cannabis Producers Become Profitable?

    Hint: Most are years away from delivering consistent profits. But there's one notable exception.

  • High Tide Announces Canna Cabana in Bonnyville as 14th Location Selling Recreational Cannabis in Alberta
    CNW Group

    High Tide Announces Canna Cabana in Bonnyville as 14th Location Selling Recreational Cannabis in Alberta

    CALGARY , Aug. 22, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that the Canna Cabana retail store located at Unit #3, 5506 50th Avenue in the city of Bonnyville (the "Bonnyville Store") received its first delivery of cannabis products from Alberta Gaming, Liquor and Cannabis ("AGLC") and has begun selling recreational cannabis for adult use. Grand opening festivities will be held at the Bonnyville Store on Saturday, August 24 .

  • New Study Shows 14% of Americans Use CBD
    Motley Fool

    New Study Shows 14% of Americans Use CBD

    Yet cannabis products represent a largely untapped market in the U.S.

  • 10 Marijuana Stocks That Could See 100% Gains, If Not More
    InvestorPlace

    10 Marijuana Stocks That Could See 100% Gains, If Not More

    The past several months haven't been particularly kind to cannabis stocks, as the hope (and hype) of the long-term potential collides with short-term reality. That is, most of these companies have spent heavily to take the lead in a highly contested race, but don't yet have the scale needed to drive actual profits.That day is still coming, at least for several of the names in the business. The question is, which ones will be left standing, picking up the pieces of an ever-growing industry?Nobody knows for sure; it's unlikely that even the companies' chiefs are entirely convinced themselves they're being built to last. But, with the marijuana industry having only scratched the surface of what it can be, and likely will be, there's little doubt that at least some of these names could double their current values.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Marijuana Stocks to Buy Now Here's a rundown of the top ten cannabis stocks most likely to dish out a triple-digit gain, sooner or later. Canopy Growth (CGC)Source: Shutterstock It's arguably the name that started cannabis-mania, as Canopy Growth (NYSE:CGC) was the first name to attract a major partner's money. In October 2017, booze company Constellation Brands (NYSE:STZ) bought a 10% stake in Canopy Growth, then in August of last year an additional $4 billion investment in CGC stock made Constellation a near-40% stakeholder. The underlying plan was ultimately ensuring access to a supply for the time when a launch of a cannabis-infused beverage made sense.Since then, the relationship became so strained that a frustrated Constellation management team forced Canopy's CEO Bruce Linton out of the role. An aggressive acquisition spree chewed up more money well before it was ready to drive a return on the investment.Still, the dozen or so acquisitions Canopy Growth has made over the course of the past year gives the organization a wide array of horizontally and vertically minded ways to monetize cannabis at some point in the future. Charlotte's Web Holdings (CWBHF)Source: Shutterstock Don't let the OTC listing fool you. With a market cap of nearly $1 billion and $86 million worth of revenue for its past four reported quarters, Charlotte's Web Holdings (OTCMKTS:CWBHF) is a more legitimate company than many of its exchange-listed counterparts. An over-the-counter listing is just less of a hassle.Charlotte's Web Holdings is uniquely positioned. It's not waiting on legalization of recreational marijuana in the U.S. because it doesn't have to. It already offers CBD oil, and capsules, in the United States and can deliver their product -- legally -- in the mail to anywhere in the U.S. * The 10 Best Cheap Stocks to Buy Right Now Perhaps more compelling, Charlotte's Web Holdings is already turning a profit. Granted, it's not a jaw-dropping bottom line. Last quarter's net income was a modest $2.2 million. It's evidence that the business can be profitable though. Net margins should improve as the company scales up. Aurora Cannabis (ACB)Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. But, Aurora Cannabis (NYSE:ACB) is certainly no slouch on that front. It recently closed on the Hempco deal first announced in April, rounding outs rather robust portfolio too.It was self-serving to be sure, but Aurora CEO Terry Booth wasn't off-base when he said of the closed Hempco acquisition "we have assembled a world-class portfolio of high-quality hemp assets that together form the basis of a strong new operating division that will develop CBD-from-hemp around the world."Aurora Cannabis is also an interesting play simply because it's not trying to be all things to all people. Although it's not terribly easy to distinguish just yet, this company is focused more on medical marijuana, and less on recreational usage.It matters. Although it's more difficult, prices and therefore margins are stronger within the medical marijuana market, where Aurora is quickly demonstrating proficiency. GW Pharmaceuticals (GWPH)Source: Shutterstock It's a name that is often left out of the discussion because (1) it's not looking to capitalize on the ongoing legalization of recreational marijuana, and (2) it has been around for years. But GW Pharmaceuticals (NASDAQ:GWPH) has absolutely earned a spot on any list of cannabis stocks positioned to double in the foreseeable future.GW Pharmaceuticals is, as the name suggests, a pharmaceutical developer. It has worked diligently to extract the full health benefits of cannabidiol, or CBD, for prescription use. It convinced the Food and Drug Administration of that potential in June of last year, securing approval for CBD-based Epidiolex as a means of treating seizures … the first CBD-based drug permitted in the U.S. * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The response has been nothing short of incredible. Some observers were expecting Epidiolex to reach a total of $65 million, total, this year. By the end of the second quarter, GW Pharmaceuticals had actually sold $102 million worth of the drug. Hexo (HEXO)Source: Shutterstock It wasn't one of the names batted around a great deal when marijuana stocks were all the rage during the middle of last year. Since then, Hexo (NYSE:HEXO) has managed to make some noise for itself.Hexo, for the unfamiliar, is building itself from the ground up, specifically to cultivate partnerships with bigger players than can carve out market share better than it ever could on its own. It calls it a "hub and spoke" model, where it serves as the hub and supplies cannabis to various partners at the other end of the spoke. There's room for several.It already has one such partner: Molson Coors Brewing (NYSE:TAP) is looking to build a cannabis beverage brand with Hexo. Other partners with other focal points will be added in time.The hard part about the strategy is, Hexo doesn't appear to be in a hurry to execute it. That patience, however, may ultimately be to the company's advantage. Tilray (TLRY)Source: Shutterstock It's curious. The consensus rating on Tilray (NASDAQ:TLRY) shares is only a little better than a 'Hold.' But, the consensus target is a healthy $64.40 per share. That's more than twice the current price of TLRY stock.It's not an unusual nuance within the cannabis industry at this time. Analysts aren't quite sure how to value these names, most of which are startups, and all of which are being lifted at least a little by hype. It's not easy to see the line dividing what's likely, and what's possible.Still, the average target for Tilray shares marks one of the biggest upsides the professionals expect to see come to fruition. * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure Tilray offers a variety of products, including extracts and dried flower, for users seeking THC as well as CBD. It also sells products on five different continents, making it a geographically diverse player. Cara Therapeutics (CARA)Source: Shutterstock As was the case with GW Pharmaceuticals, Cara Therapeutics (NASDAQ:CARA) has largely been omitted from the discussion of cannabis stocks as a whole because it's not a newcomer catering mostly to recreational users. It's still a cannabis name though, or will be, eventually.Cara's claim to fame at this time is a developmental drug currently just referred to as CR845. It's a prospective alternative to opioids, which are effective painkillers, but also highly addictive. CR845 also has absolutely nothing to do with cannabis.Cara Therapeutics' CR701, however, is a prospective painkiller that specifically uses cannabinoid agonists to block the body's pain receptors. While still years away from commercialization, the clinical trial setting certainly legitimizes cannabis as real medicine. OrganiGram Holdings (OGI)Source: Shutterstock If nothing else, OrganiGram Holdings (NASDAQ:OGI) has earned a look because it's one of the few names in the cannabis business that's profitable. Indeed, with its numbers reported in July, it has been profitable for four straight quarters.The underpinnings for that unusual claim in the cannabis realm largely reflects the company's growing acumen. Even though last quarter's cash production costs grew from 65 cents per gram to 95 cents per gram, that's still less than the $1.42 per gram Aurora had to spend to supply itself, or the $1.48 Tilray laid out to grow its own supply. * The 10 Best Marijuana Stocks to Buy Now Still, the big cost jump last quarter? Don't read too much into it. The costs were associated with an experiment designed to further improve yield. It failed, so the company won't be attempting it again. Medipharm Labs (MEDIF)Source: Shutterstock As was the case with Charlotte's Web Holdings, don't be put off by the OTC listing of Medipharm Labs (OTCMKTS:MEDIF). This company is also on firmer footing than many of its exchange-listed rivals, even if most cannabis investors have never heard of it.Medipharm Labs specializes in one narrow sliver of the budding cannabis arena … extraction. Leveraging technology with experience, this company can turn raw marijuana into pure cannabis that meets the exacting standards most CBD suppliers expect in the current, scrutinizing environment.It's still bleeding money in a big way, here at the industry's infancy. Patience is merited though. This year's top line is projected to grow nearly 40%, followed by another 32% revenue leap next year.That still won't be enough to drag Medipharm out of the red, but scale should pay off soon enough. Cronos Group (CRON)Source: Shutterstock Finally, add Cronos Group (NASDAQ:CRON) to your list of cannabis stocks with the potential to double at some point in the future.Cronos Group does a little of everything, from cannabis research to product development consumer sales. It operates three brands: Peace Naturals, Cove and Spinach. And, like Tilray, it has a presence on five different continents.Perhaps the most bullish argument for CRON stock at this time, however, is the recently initiated coverage from Piper Jaffray. Analyst Michael Lavery notes "We expect Cronos to have modest near-term revenues from Canadian cannabis production, but believe it has significant potential growth opportunities with CBD products in the US, including through its pending acquisition of the Lord Jones brand." * 7 Marijuana Penny Stocks That I May Buy Its partnership with Altria Group (NYSE:MO) also bodes well, even if it has accomplished little so far.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post 10 Marijuana Stocks That Could See 100% Gains, If Not More appeared first on InvestorPlace.

  • 3 Compelling Catalysts for Aurora Cannabis Stock
    InvestorPlace

    3 Compelling Catalysts for Aurora Cannabis Stock

    I'm going to be blunt straight off the bat. Although the topic of the day is Aurora Cannabis (NYSE:ACB), we can essentially lump all the major marijuana players together. That's what the markets are doing and for good reason. At the end of the day, ACB stock is a race against time.What do I mean by this? Simply, we know that virtually all marijuana-based investments, even top-shelf names like Aurora Cannabis stock, have challenged fundamentals. Most financial institutions won't touch the sector because technically and legally, it could all go belly up without much warning.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFurther, even though some weed firms have forged lucrative partnerships -- look at Cronos Group (NASDAQ:CRON) and Altria Group (NYSE:MO) -- it's not enough to garner widespread credibility. One of the main criticisms of ACB stock and its ilk is that the underlying company is expanding aggressively.That's resulted in a cash burn problem that has weighed on Aurora Cannabis stock. * 10 Undervalued Stocks With Breakout Potential On the other hand, we know about the paradigm-shattering potential for this "agricultural" industry. For instance, I've routinely used the phrase -- to annoyance perhaps -- that marijuana represents a transformative investment. Primarily, I keep saying this because this industry made the hardest of shifts, from non-existence (legally speaking) to existence; in other words, from zero to something.And that's why I'm using the racing analogy for ACB stock. Aurora Cannabis and its big brethren are hoping that their flawed financials buy them enough time to actualize marijuana's potential. I believe that the top players and some smaller, promising outfits can. Here are three reasons why: Harvard Research Offers Groundbreaking Medical Potential for ACB StockPancreatic cancer is among the nastiest of all cancers, imposing a very low survival rate. Infamously and tragically, it took the life of Apple's (NASDAQ:AAPL) Steve Jobs. But now, new hope for a cannabis-related breakthrough should immediately intrigue anyone holding Aurora Cannabis stock.Researchers at Harvard University's Dana-Farber Cancer Institute released a report indicating that a cannabis compound offers "significant therapy potential" for treating pancreatic cancer. Specifically, the researchers isolated and extracted this compound, known as a flavonoid. Through genetic engineering, they ramped up production of this flavonoid, and applied it against malignant tumors.The study noted that the application resulted in metastatic tumor cell kills. Based on the researchers' enthusiasm for the outcome, this news has incredibly positive implications for ACB stock.I'm not suggesting that Aurora Cannabis stock will suddenly rise on this development. What I am saying is that mainstream interest toward at least medical-cannabis legalization will spike. And this really has the potential for sparking full federal legalization.It's also a political no-brainer. What dimwit would stand in the way of promising cancer therapies because they have moral or religious reservations? If many lives can be saved, the obviously ethical choice is full or otherwise unhindered federal legalization. A Prolonged Recession May Benefit Aurora Cannabis StockVery few companies or sectors have performed well in recent weeks, and that goes for marijuana companies. When you have the Dow Jones dropping 800 points in a single session, you know investors have serious concerns. Under such an environment, most stocks simply plummet in a panicked reaction.Unfortunately, many if not most of the names that recently experienced volatility will probably suffer more along the road. In this brave new world of globalization, our economy doesn't operate in a vacuum. Increasingly, we are more dependent on each other.And that's really the underlying pain of the U.S.-China trade war. Of course, when you're talking about China, you must engage delicately. As you know, President Trump hardly adopts tactful diplomacy.But when one of the reasons why I like Aurora Cannabis stock in this environment is that China is not in the picture. Indeed, it's never been in the picture. For instance, China has draconian drug laws, and that probably won't change in our lifetimes.Put another way, marijuana is one of those rare industries that is both vibrant and doesn't have a care in the world about China. This dynamic also incentivizes federal legalization, especially if people get laid off from trade-impacted industries. Technicals Support a ComebackAdmittedly, the volatility in the weed market is nothing short of scary. Even a top-shelf name like ACB stock isn't immune from extreme hemorrhaging. Since mid-March of this year, shares have lost a staggering 38%.However, I also feel that the sector is either at or approaching a bottom. Right now, we have no shortage of downright terrible news weighing on weed. Off the top of my head, we've had a slew of disappointing earnings results. We also witnessed credibility-damaging controversies, such as CannTrust's (NYSE:CTST) illegal growing.If that weren't bad enough, the FBI is actively courting whistleblowers for bad marijuana players. * The 10 Best Marijuana Stocks to Buy Now Yet despite the overwhelming negativity, ACB stock has slowed its descent. This, along with the other tailwinds I mentioned, gives me confidence that Aurora Cannabis can buy itself the required time.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Compelling Catalysts for Aurora Cannabis Stock appeared first on InvestorPlace.

  • 4 of the Most Efficient Marijuana Stocks
    Motley Fool

    4 of the Most Efficient Marijuana Stocks

    These cannabis stocks should have some of the best growing yields per square foot in the industry.

  • Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
    Zacks

    Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know

    Aurora Cannabis Inc. (ACB) closed the most recent trading day at $5.93, moving +1.54% from the previous trading session.

  • Where Does Buttigieg Stand on Cannabis Legalization?
    Market Realist

    Where Does Buttigieg Stand on Cannabis Legalization?

    Compared to his fellow Democratic nominees, Buttigieg hasn't been too vocal on cannabis legalization. However, he supports it.

  • Marijuana company boards are shockingly more white than Fortune 100 boards
    Yahoo Finance

    Marijuana company boards are shockingly more white than Fortune 100 boards

    Despite mostly equal marijuana usage rates along racial lines, the boards at the top marijuana companies are still shockingly white.